These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 7865886)

  • 1. Nerve growth factor regulates the expression and activity of p33cdk2 and p34cdc2 kinases in PC12 pheochromocytoma cells.
    Buchkovich KJ; Ziff EB
    Mol Biol Cell; 1994 Nov; 5(11):1225-41. PubMed ID: 7865886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine.
    Gollapudi L; Neet KE
    J Neurosci Res; 1997 Aug; 49(4):461-74. PubMed ID: 9285522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin A recruits p33cdk2 to the cellular transcription factor DRTF1.
    Bandara LR; Adamczewski JP; Zamanian M; Poon RY; Hunt T; Thangue NB
    J Cell Sci Suppl; 1992; 16():77-85. PubMed ID: 1297652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of the synthesis and activity of the major cyclin-dependent kinases, p34cdc2, p33cdk2, and p34cdk4, during cell cycle entry and progression in normal human T lymphocytes.
    Lucas JJ; Szepesi A; Domenico J; Tordai A; Terada N; Gelfand EW
    J Cell Physiol; 1995 Nov; 165(2):406-16. PubMed ID: 7593219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation.
    Kiess M; Gill RM; Hamel PA
    Cell Growth Differ; 1995 Oct; 6(10):1287-98. PubMed ID: 8845306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
    Morice WG; Wiederrecht G; Brunn GJ; Siekierka JJ; Abraham RT
    J Biol Chem; 1993 Oct; 268(30):22737-45. PubMed ID: 8226784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of specific E2F complexes by the v-mos oncogene.
    Afshari CA; Rhodes N; Paules RS; Mudryj M
    Oncogene; 1997 Jun; 14(25):3029-38. PubMed ID: 9223666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cyclin A-protein kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F-cyclin A complex.
    Devoto SH; Mudryj M; Pines J; Hunter T; Nevins JR
    Cell; 1992 Jan; 68(1):167-76. PubMed ID: 1310073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1.
    Yan GZ; Ziff EB
    J Neurosci; 1995 Sep; 15(9):6200-12. PubMed ID: 7666202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cell-cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor.
    Khwaja F; Djakiew D
    Mol Carcinog; 2003 Mar; 36(3):153-60. PubMed ID: 12619038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rb-related p107 protein can suppress E2F function independently of binding to cyclin A/cdk2.
    Smith EJ; Nevins JR
    Mol Cell Biol; 1995 Jan; 15(1):338-44. PubMed ID: 7799940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2.
    Poon RY; Yamashita K; Adamczewski JP; Hunt T; Shuttleworth J
    EMBO J; 1993 Aug; 12(8):3123-32. PubMed ID: 8393783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory interactions among E2Fs and cell cycle control proteins.
    Cobrinik D
    Curr Top Microbiol Immunol; 1996; 208():31-61. PubMed ID: 8575212
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs.
    Rhodes N; Innes CL; Propst F; Paules RS
    Oncogene; 1997 Jun; 14(25):3017-27. PubMed ID: 9223665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential activation of cyclin and cyclin-dependent kinase genes by adenovirus E1A12S cDNA product.
    Ishii T; Shimizu M; Kanayama Y; Nakada S; Nojima H; Oda K
    Exp Cell Res; 1993 Oct; 208(2):407-14. PubMed ID: 8375470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors.
    Clark W; Gillespie DA
    Cell Growth Differ; 1997 Apr; 8(4):371-80. PubMed ID: 9101083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.
    Puri PL; Balsano C; Burgio VL; Chirillo P; Natoli G; Ricci L; Mattei E; Graessmann A; Levrero M
    Oncogene; 1997 Mar; 14(10):1171-84. PubMed ID: 9121766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal regulation of cyclin A-p107 and p33cdk2 complexes binding to a human thymidine kinase promoter element important for G1-S phase transcriptional regulation.
    Li LJ; Naeve GS; Lee AS
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3554-8. PubMed ID: 8475104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 2 and cyclin A interaction with E2F are targets for tyrosine induction of B16 melanoma terminal differentiation.
    Rieber M; Rieber MS
    Cell Growth Differ; 1994 Dec; 5(12):1339-46. PubMed ID: 7696182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
    Kiyokawa H; Richon VM; Rifkind RA; Marks PA
    Mol Cell Biol; 1994 Nov; 14(11):7195-203. PubMed ID: 7935434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.